Display options
Cite
Forte IM, Indovina P, Montagnaro S, et al. The Oncolytic Caprine Herpesvirus 1 (CpHV-1) Induces Apoptosis and Synergizes with Cisplatin in Mesothelioma Cell Lines: A New Potential Virotherapy Approach. Viruses. 2021;13(12)doi: 10.3390/v13122458.
Forte, I. M., Indovina, P., Montagnaro, S., Costa, A., Iannuzzi, C. A., Capone, F., Camerlingo, R., Malfitano, A. M., Pentimalli, F., Ferrara, G., Quintiliani, M., Portella, G., Giordano, A., & Ciarcia, R. (2021). The Oncolytic Caprine Herpesvirus 1 (CpHV-1) Induces Apoptosis and Synergizes with Cisplatin in Mesothelioma Cell Lines: A New Potential Virotherapy Approach. Viruses, 13(12), . https://doi.org/10.3390/v13122458
Forte, Iris Maria, et al. "The Oncolytic Caprine Herpesvirus 1 (CpHV-1) Induces Apoptosis and Synergizes with Cisplatin in Mesothelioma Cell Lines: A New Potential Virotherapy Approach." Viruses vol. 13,12 (2021). doi: https://doi.org/10.3390/v13122458
Forte IM, Indovina P, Montagnaro S, Costa A, Iannuzzi CA, Capone F, Camerlingo R, Malfitano AM, Pentimalli F, Ferrara G, Quintiliani M, Portella G, Giordano A, Ciarcia R. The Oncolytic Caprine Herpesvirus 1 (CpHV-1) Induces Apoptosis and Synergizes with Cisplatin in Mesothelioma Cell Lines: A New Potential Virotherapy Approach. Viruses. 2021 Dec 08;13(12). doi: 10.3390/v13122458. PMID: 34960727; PMCID: PMC8703924.
Copy Download .nbib Format: NLM
Share it on

Viruses. 2021 Dec 08;13(12). doi: 10.3390/v13122458.

The Oncolytic Caprine Herpesvirus 1 (CpHV-1) Induces Apoptosis and Synergizes with Cisplatin in Mesothelioma Cell Lines: A New Potential Virotherapy Approach.

Viruses

Iris Maria Forte, Paola Indovina, Serena Montagnaro, Aurora Costa, Carmelina Antonella Iannuzzi, Francesca Capone, Rosa Camerlingo, Anna Maria Malfitano, Francesca Pentimalli, Gianmarco Ferrara, Massimiliamo Quintiliani, Giuseppe Portella, Antonio Giordano, Roberto Ciarcia

Affiliations

  1. Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, 80131 Naples, Italy.
  2. Institute for High Performance Computing and Networking, National Research Council of Italy (ICAR-CNR), 80131 Naples, Italy.
  3. Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA.
  4. Department of Veterinary Medicine and Animal Productions, University of Naples "Federico II", 80137 Naples, Italy.
  5. Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.
  6. Experimental Pharmacology Unit-Laboratories of Naples and Mercogliano (AV), Istituto Nazionale per lo Studio e la Cura deiTumori "Fondazione G. Pascale", 80131 Naples, Italy.
  7. Dipartimento Scienze Mediche Traslazionali, Università di Napoli "Federico II", 80131 Naples, Italy.
  8. Department of Life, Health and Environmental Sciences, University of L'Aquila, 67100 L'Aquila, Italy.

PMID: 34960727 PMCID: PMC8703924 DOI: 10.3390/v13122458

Abstract

Malignant mesothelioma (MM) is an aggressive asbestos-related cancer, against which no curative modalities exist. Oncolytic virotherapy is a promising therapeutic approach, for which MM is an ideal candidate; indeed, the pleural location provides direct access for the intra-tumoral injection of oncolytic viruses (OVs). Some non-human OVs offer advantages over human OVs, including the non-pathogenicity in humans and the absence of pre-existing immunity. We previously showed that caprine herpesvirus 1 (CpHV-1), a non-pathogenic virus for humans, can kill different human cancer cell lines. Here, we assessed CpHV-1 effects on MM (NCI-H28, MSTO, NCI-H2052) and non-tumor mesothelial (MET-5A) cells. We found that CpHV-1 reduced cell viability and clonogenic potential in all MM cell lines without affecting non-tumor cells, in which, indeed, we did not detect intracellular viral DNA after treatment. In particular, CpHV-1 induced MM cell apoptosis and accumulation in G0/G1 or S cell cycle phases. Moreover, CpHV-1 strongly synergized with cisplatin, the drug currently used in MM chemotherapy, and this agent combination did not affect normal mesothelial cells. Although further studies are required to elucidate the mechanisms underlying the selective CpHV-1 action on MM cells, our data suggest that the CpHV-1-cisplatin combination could be a feasible strategy against MM.

Keywords: apoptosis; caprine herpesvirus 1 (CpHV-1); cisplatin; malignant mesothelioma (MM); oncolytic virus (OV); synergism

References

  1. Cancer Res. 2008 Jun 15;68(12):4882-92 - PubMed
  2. Cancers (Basel). 2020 Jul 11;12(7): - PubMed
  3. Oncoimmunology. 2015 Dec 8;5(1):e1115641 - PubMed
  4. Oncolytic Virother. 2015 Sep 10;4:133-40 - PubMed
  5. Cell Cycle. 2014;13(4):652-65 - PubMed
  6. Science. 1990 Nov 30;250(4985):1262-6 - PubMed
  7. J Thorac Dis. 2013 Dec;5(6):E254-307 - PubMed
  8. Int J Mol Sci. 2018 May 30;19(6): - PubMed
  9. Vet Immunol Immunopathol. 2005 Feb 10;103(3-4):283-93 - PubMed
  10. Exp Biol Med (Maywood). 2019 Sep;244(12):983-991 - PubMed
  11. Front Cell Infect Microbiol. 2018 Nov 19;8:396 - PubMed
  12. Lancet Oncol. 2021 Feb;22(2):190-197 - PubMed
  13. Nat Biotechnol. 2012 Jul 10;30(7):658-70 - PubMed
  14. Front Oncol. 2017 Aug 24;7:179 - PubMed
  15. Front Immunol. 2017 May 15;8:555 - PubMed
  16. Semin Cancer Biol. 2020 Apr;61:11-22 - PubMed
  17. Ann Transl Med. 2017 Jun;5(11):238 - PubMed
  18. Drug Deliv. 2018 Nov;25(1):1950-1962 - PubMed
  19. Cancers (Basel). 2020 Nov 28;12(12): - PubMed
  20. Transl Lung Cancer Res. 2020 Feb;9(Suppl 1):S28-S38 - PubMed
  21. Hum Cell. 2002 Sep;15(3):151-9 - PubMed
  22. J Adv Res. 2015 May;6(3):319-30 - PubMed
  23. Microb Pathog. 2019 Nov;136:103663 - PubMed
  24. Oncotarget. 2017 May 31;8(60):102617-102639 - PubMed
  25. Biochem Pharmacol. 2020 Jul;177:113986 - PubMed
  26. Oncoimmunology. 2019 Mar 28;8(6):e1581528 - PubMed
  27. Viruses. 2019 Jun 18;11(6): - PubMed
  28. J Virol. 1999 Oct;73(10):8245-55 - PubMed
  29. Nat Commun. 2019 Mar 22;10(1):1333 - PubMed
  30. J Thorac Oncol. 2016 Feb;11(2):142-54 - PubMed
  31. Int J Mol Sci. 2020 Nov 05;21(21): - PubMed
  32. Pathogens. 2016 Feb 06;5(1): - PubMed
  33. Adv Enzyme Regul. 1984;22:27-55 - PubMed
  34. Nat Rev Cancer. 2005 Dec;5(12):965-76 - PubMed
  35. Cancer Biol Ther. 2006 Jan;5(1):48-53 - PubMed
  36. Lancet Oncol. 2019 Feb;20(2):239-253 - PubMed
  37. Int J Mol Sci. 2020 Oct 04;21(19): - PubMed
  38. J Gen Virol. 1998 Aug;79 ( Pt 8):1983-7 - PubMed
  39. Schweiz Arch Tierheilkd. 1979;121(12):655-62 - PubMed
  40. Cancer Gene Ther. 2006 Nov;13(11):975-92 - PubMed
  41. Cancer Gene Ther. 2010 May;17(5):344-55 - PubMed
  42. Front Oncol. 2020 Jan 24;9:1519 - PubMed
  43. J Thorac Oncol. 2020 Jan;15(1):29-49 - PubMed
  44. Hum Gene Ther. 2010 Jan;21(1):51-64 - PubMed
  45. Cell. 1999 Dec 23;99(7):817-27 - PubMed
  46. Sci Rep. 2017 Aug 23;7(1):9176 - PubMed
  47. Front Oncol. 2019 Jul 12;9:564 - PubMed
  48. Cancer Biol Ther. 2019;20(1):42-51 - PubMed
  49. Cancer Gene Ther. 2002 Dec;9(12):1062-7 - PubMed
  50. Lancet Oncol. 2018 Mar;19(3):e161-e172 - PubMed
  51. Lancet Oncol. 2017 Sep;18(9):e532-e542 - PubMed
  52. J Biol Chem. 2003 Jul 11;278(28):25964-9 - PubMed
  53. J Gene Med. 2010 Aug;12(8):681-92 - PubMed
  54. Lancet. 2005 Jul 30-Aug 5;366(9483):397-408 - PubMed
  55. Nat Med. 2001 Jul;7(7):781-7 - PubMed

Publication Types

Grant support